Supply Chain Intelligence

Alnylam Pharmaceuticals, Inc. Supply Chain

ALNY supply chain intelligence for Alnylam Pharmaceuticals, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.

ALNY ·Last updated 2026-07-29 · Interactive map →

Data compiled by Redley Lamar · ChainSifter Intelligence

5Suppliers
6Customers
2Debt Items
20Related Chains

Alnylam Pharmaceuticals, Inc. Suppliers

TickerNameConfidenceEvidence
REGENERON REGENERON 90% In November 2022, Regeneron exercised its right under the C5 Co-Co Collaboration Agreement to opt-out of the further development and commercialization of cemdisiran monotherapy.
ROCHE ROCHE 85% As of the Effective Date, we identified the following promises in the Roche Agreement that were evaluated under the scope of Accounting Standards Codification, or ASC, Topic 606, Revenue from Contrac…
DYN Dyne Therapeutics, Inc. 72% Reciprocal relationship from DYN graph: ces and our business and operations, including clinical trials, could be disrupted by any problems with our significant third-party vendors. We engage a number…
IBIO iBio, Inc. 72% Reciprocal relationship from IBIO graph: Reciprocal relationship from ALNY graph: Reciprocal relationship from IBIO graph: t of our agreement with them. Any of our drug candidates, therefore, may be …
IONS Ionis Pharmaceuticals, Inc. 72% Reciprocal relationship from IONS graph: Reciprocal relationship from ALNY graph: Reciprocal relationship from IONS graph: nt of certain development, regulatory and sales events. We will also reimbur…

Alnylam Pharmaceuticals, Inc. Customers

TickerNameConfidenceEvidence
REGN Regeneron Pharmaceuticals, Inc. 85% bal, strategic collaboration with Regeneron Pharmaceuticals, Inc., or Regeneron, to discover, develop and commercialize RNAi therapeutics for a broad range of diseases by addressing therapeutic targe…
REGN Regeneron Pharmaceuticals, Inc. 85% Reciprocal relationship from REGN graph: Reciprocal relationship from ALNY graph: Reciprocal relationship from REGN graph: Reciprocal relationship from ALNY graph: Reciprocal relationship from REGN g…
DYN Dyne Therapeutics, Inc. 72% Reciprocal relationship from DYN graph: Reciprocal relationship from ALNY graph: Reciprocal relationship from DYN graph: Reciprocal relationship from ALNY graph: Reciprocal relationship from DYN grap…
IBIO iBio, Inc. 72% Reciprocal relationship from IBIO graph: Biohaven, Ltd., Structure Therapeutics, Inc., Viking Therapeutics, Inc., Veru Inc., Zealand Pharma A/S, Metsera, Inc., Terns Pharmaceuticals, Inc., Skye Biosc…
IONS Ionis Pharmaceuticals, Inc. 72% Reciprocal relationship from IONS graph: ible to receive tiered royalties up to 30 percent on net sales. From inception through December 31, 2025, we have generated more than $125 million in payments…
VKTX Viking Therapeutics, Inc. 72% Reciprocal relationship from VKTX graph: y a given regulatory authority, such regulatory authority will determine that any of our clinical trials comply with GCP regulations. In addition, our clinica…

Alnylam Pharmaceuticals, Inc. Debt Obligations

InstrumentDescriptionConfidenceEvidence
ALNY-DEBT-7692 Xbrl Convertible 90% xbrl convertible detail from xbrl 2025-12-31.
ALNY-DEBT Debt stack $3.0B 90% Market cache reports total debt of $3.0B.

Alnylam Pharmaceuticals, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Alnylam Pharmaceuticals, Inc..

Alnylam Pharmaceuticals, Inc. Ownership

HolderNameConfidenceEvidence
ALNY-OWNER-FMR-LLC FMR LLC 90% 13F overlay lists FMR LLC as top holder; 796 tracked holders.

Alnylam Pharmaceuticals, Inc. Extended Supply Chain Network

TickerNameChain IndexHopsRelationship Types
FHTX Foghorn Therapeutics Inc. 100.00 2
WHWK Whitehawk Therapeutics, Inc. 100.00 2
BIOA BioAge Labs, Inc. 100.00 2
CYTK Cytokinetics, Incorporated 100.00 2
CPRX Catalyst Pharmaceuticals, Inc. 100.00 2
CYTOF Altamira Therapeutics Ltd. 100.00 2
CANF Can-Fite BioPharma Ltd. 100.00 2
CTNM Contineum Therapeutics, Inc. 100.00 2
BLRX BioLineRx Ltd. 100.00 2
DAWN Day One Biopharmaceuticals Inc 100.00 2
ANRO Alto Neuroscience, Inc. 100.00 2
AXSM Axsome Therapeutics, Inc. 100.00 2
CRBP Corbus Pharmaceuticals Holdings, Inc. 100.00 2
CRBU Caribou Biosciences, Inc. 100.00 2
CTMX CytomX Therapeutics, Inc. 100.00 2
ALXO ALX Oncology Holdings Inc. 100.00 2
DEO Diageo plc 100.00 2
BNBX BNB Plus Corp. 100.00 2
ANL Adlai Nortye Ltd. 100.00 2
CBIO Crescent Biopharma, Inc. 100.00 2
View ALNY supply chain intel →

Explore the full interactive supply chain map for Alnylam Pharmaceuticals, Inc..

Open ALNY supply chain map →
ChainSifter · Guerilla Finance Terms Disclaimer ← Back to Map